Brief: Adaptimmune Reports Positive Data In Its Surpass Trial Outlines Plans For Advanced Clinical Development In Multiple Mage-A4 Positive Solid Tumors

Adaptimmune Therapeutics

09/09/2022 12:20

Sept 9 (Reuters) - Adaptimmune Therapeutics PLC  ADAP.O :
    * ADAPTIMMUNE REPORTS POSITIVE DATA IN ITS SURPASS TRIAL;
OUTLINES
PLANS FOR ADVANCED CLINICAL DEVELOPMENT IN MULTIPLE MAGE-A4
POSITIVE SOLID TUMORS
    * ADAPTIMMUNE - ACROSS ALL TUMOR TYPES IN SURPASS TRIAL,
RESPONSES
OBSERVED IN FIVE SOLID TUMOR TYPES IN 43 HEAVILY PRE-TREATED
PATIENTS WITH ORR OF 33%
    * ADAPTIMMUNE - ACROSS NON-SARCOMA TUMORS, SIGNIFICANTLY
HIGHER
RESPONSE RATES COMPARED WITH THE FIRST-GENERATION MAGE-A4
TARGETED PRODUCT
    * ADAPTIMMUNE -  FURTHER CLINICAL DEVELOPMENT PLANNED IN
OVARIAN
(SURPASS-3), UROTHELIAL, AND HEAD & NECK CANCERS
    * ADAPTIMMUNE - 44% ORR WITH SINGLE DOSE OF ADP-A2M4CD8 IN
25
HEAVILY PRE-TREATED PATIENTS WITH LATE-STAGE OVARIAN,
UROTHELIAL, AND HEAD & NECK CANCERS

Source text for Eikon:  ID:nFWN30G0JZ 
Further company coverage:  ADAP.O 

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))